We recently published 10 Firms Dominating the Market; 5 at All-Time Highs. Travere Therapeutics, Inc. (NASDAQ:TVTX) is one of ...

In FSGS, podocytes are damaged, like a net with torn holes, allowing protein to leak into the urine, creating a harmful ...

Sparsentan therapy was associated with sustained decline in proteinuria and lower likelihood of progression to kidney failure ...

Celebrations may be in order for Travere Therapeutics, Inc. (NASDAQ:TVTX) shareholders, with the analysts delivering a significant upgrade to their statutory estimates for the company. Consensus ...

Fintel reports that on November 4, 2025, Piper Sandler maintained coverage of Travere Therapeutics (NasdaqGM:TVTX) with a ...

October 2025 saw a wave of M&As and biotech deals in various therapeutic fields, particularly for therapies addressing ...

The benefits are observed across patient subtypes and potentially offer the chance to avoid dialysis and implement a new standard of care.

Travere Therapeutics, Inc. (($TVTX)) has held its Q3 earnings call. Read on for the main highlights of the call. Travere Therapeutics, Inc.

Ligand is increasing its 2025 full year financial guidance. The Company now expects total core revenue of $225 million to ...

Information Services Group (ISG) , a global AI-centered technology research and advisory firm, has launched a research study examining providers in the ServiceNow ecosystem that are helping ...

Re-Time Pty Ltd (RTPL) today announced the launch of the retimer Ring, the first smart ring solution developed by an Australian company to help people improve sleep and overall wellbeing. Building on ...

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences: Presenting on Tuesday, November 11, 2025, at 9:00 a.m ...